LEXINGTON, Ky. – December 1, 2022 – (Newswire.com)
Thynk Health and Riverain, pioneers in the healthcare artificial intelligence space, have announced a partnership between their platforms to fight lung cancer with the world’s most advanced technologies. By combining all the latest technologies, including CAD, Machine Learning, clinical NLP, recurrent neural networks, and artificial intelligence, this partnership offers an unprecedented opportunity for lung cancer screening and pulmonary nodule management.
Thynk Health is the complete cancer screening and incidental finding management solution. Utilizing state-of-the-art artificial intelligence and deep learning algorithms, Thynk Health seamlessly integrates with EHRs and health systems to mine structured and unstructured data, organizing it in powerful, simple dashboards. With advanced automation and analytics, healthcare systems are empowering their cancer screening programs with actionable intelligence to be more effective and efficient.
“Radiologists are experiencing AI as an adjunctive tool rather than the job-stealing technology previously warned by futuristic writers. This is evident in the ability to have a second set of eyes when looking for small or hilar region pulmonary nodules. When utilized in combination with advanced deep learning for language abstraction from reporting, AI technology is even more effective, allowing for radiologists to use traditional workflows rather than archaic and cumbersome second workstation solutions.” – Joey Bargo, Thynk Health Co-Founder, and Chief Product Officer
Riverain is a leading high-tech enterprise in medical artificial intelligence. Riverain ClearRead solutions significantly improve a clinician’s ability to detect disease accurately and efficiently in thoracic (lung) CT and XR images and more successfully address the challenges of early detection of lung disease. Powered by machine learning and advanced modeling, the ClearRead software tools are powered by the most advanced AI methods available to the medical imaging market. Battling growing workloads and less time, ClearRead solutions allow clinicians to complete more reads faster – saving valuable time without sacrificing performance.
“The power of Thynk Health’s AI-driven analytics abstracted from healthcare EHRs combined with Riverain’s ClearRead suite significantly improves the ability to detect lung disease, and change the lives of patients, creates a comprehensive solution for lung cancer screening and pulmonary nodule management that offers healthcare systems a new level of patient care and growth to the Lung Nodule diagnostic process.” – Jeff Timbrook, Thynk Health CEO.
Lung Cancer continues to be the leading cause of cancer death by far among all people, making up almost 25% of all cancer deaths (more than colon, breast, and prostate cancers combined). In 2022 the American Cancer Society estimates 236,740 new cases of lung cancer will be diagnosed, and 130,180 deaths from lung cancer will occur. Thynk Health and Riverain’s partnership opens a new level of opportunity for healthcare systems to identify at-risk populations and diagnose and treat those populations when in early stages, significantly increasing survival rates. With advanced technology companies, healthcare systems, and communities partnering together, we can and will win the fight against lung cancer.
Contact Information:
Thomas Croce
Marketing Manager
1-855-633-6963 x 711
Press Release Service
by
Newswire.com
Original Source:
Thynk Health and Riverian Partner to Fight Lung Cancer With Advanced AI and Deep Learning Technologies
